Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company’s approach to ...

撰文丨王聪编辑丨王多鱼排版丨水成文癌症免疫疗法通过调动免疫系统来消除肿瘤，已展现出变革性的临床前景。然而，仅有约 20% 的患者能够产生持久的治疗响应，这受到肿瘤内在的适应性抗性和肿瘤微环境（TME）内免疫抑制细胞网络的限制——首先，肿瘤细胞内在的 ...

引言结直肠癌是全球第三大常见的恶性肿瘤，也是癌症相关死亡的第二大主要原因[1]。新辅助放化疗（nCRT）是当前局部晚期直肠癌（LARC）的标准治疗方案，有助于降低肿瘤分期及局部复发风险等[2,3]。尽管该方案已显著改善患者预后，但治疗后达病理完全缓解（pCR）的患者比例仍然相对较低（10%-30%），患者的长期生存结局仍需进 ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology to include ...

A proposed model illustrating how tumor cells release PD-L1-containing small extracellular vesicles (sEVs) that suppress ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.

Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...